The grades of five Pharmaceutical stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Alimera Sciences, Inc. (NASDAQ:ALIM) is making progress this week as its rating of C (“hold”) from last week increases to a B (“buy”) rating this week. Alimera Sciences engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. For more information, get Portfolio Grader’s complete analysis of ALIM stock.
Johnson & Johnson (NYSE:JNJ) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The stock’s dividend yield is 2.6%. For more information, get Portfolio Grader’s complete analysis of JNJ stock.
Bristol-Myers Squibb Company (NYSE:BMY) improves from a C to a B rating this week. Bristol-Myers Squibb is a global company that develops, produces and sells pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of BMY stock.
This week, Watson Pharmaceuticals’ (NYSE:WPI) ratings are up from a B last week to an A. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. For more information, get Portfolio Grader’s complete analysis of WPI stock.
This week, Repros Therapeutics (NASDAQ:RPRX) pushes up from a B to an A rating. Repros Therapeutics is a development stage biopharmaceutical company focusing on the development of oral small molecule drugs for major unmet medical needs. For more information, get Portfolio Grader’s complete analysis of RPRX stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.